@article{985a023bdce84c2cbc771295e2601fda,
title = "Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1",
abstract = "Background: Recent literature documents a stronger association between nonfasting triglycerides (TG) and cardiovascular risk compared to fasting TG. Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial. Methods: Change in nonfasting TG, adjusted for baseline value, was compared between antipsychotic treatment groups using subjects with nonfasting laboratory assessments at baseline and 3 months. Results: Among the 246 subjects there were significant treatment differences in 3-month change from baseline (p = 0.009). The greatest increases in median and adjusted mean nonfasting TG levels were seen among those randomized to quetiapine (mean + 54.7 mg/dl, median + 26 mg/dl) and olanzapine (mean + 23.4 mg/dl, median + 26.5 mg/dl), while ziprasidone was neutral (mean + 0.0 mg/dl, median + 8 mg/dl), and decreases were seen with risperidone (mean - 18.4 mg/dl, median - 6.5 mg/dl) and perphenazine (mean - 1.3 mg/dl, median - 22 mg/dl). Pairwise comparisons indicated a significant between-group difference for perphenazine vs. olanzapine (p = 0.002) and a trend for perphenazine vs. quetiapine (p = 0.006). Conclusions: This analysis provides further evidence for differential antipsychotic metabolic liabilities, and confirms signals for the effects of olanzapine and quetiapine on serum TG seen in earlier CATIE analyses. Future consensus recommendations will clarify the role of nonfasting TG monitoring in routine clinical practice.",
keywords = "Antipsychotic, Cardiovascular risk, Lipids, Nonfasting, Schizophrenia, Triglycerides",
author = "Meyer, {Jonathan M.} and Davis, {Vicki G.} and McEvoy, {Joseph Patrick} and Goff, {Donald C.} and Nasrallah, {Henry A.} and Davis, {Sonia M.} and Daumit, {Gail L.} and John Hsiao and Swartz, {Marvin S.} and Stroup, {T. Scott} and Lieberman, {Jeffrey A.}",
note = "Funding Information: Jeffrey A. Lieberman, M.D.: Dr. Lieberman reports having received research funding from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica Products, and Pfizer Inc.; and consulting and educational fees from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Eli Lilly and Co., Forest Pharmaceutical Company, GlaxoSmithKline, Janssen Pharmaceutica Products, Novartis, Pfizer, Inc., and Solvay. Funding Information: Henry A. Nasrallah, M.D.: Dr. Nasrallah reports receiving fees for consulting, advising or speaking for Abbott Labs, AstraZeneca Pharmaceuticals LP, Janssen Pharmaceutica, Pfizer, Inc. and Solvay, research grant support from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Janssen Pharmaceutica, Eli Lilly and Co., Pfizer, Inc., Sanofi-Avenits, and NIMH. Funding Information: Joseph P. McEvoy, M.D.: Dr. McEvoy reports having received research funding from AstraZeneca Pharmaceuticals LP, Forest Research Institute, Eli Lilly and Co., Janssen Pharmaceutica, and Pfizer, Inc.; consulting or advisory board fees from Pfizer, Inc. and Bristol-Myers Squibb; and lecture fees from Janssen Pharmaceutica, and Bristol-Myers Squibb. Funding Information: The CATIE Trials were supported by National Institute of Mental health (NIMH) grant #N01MH90001. The NIMH and study principal investigators are responsible for the design and conduct of the trial, and the primary analyses. There is no industry involvement in these activities. ",
year = "2008",
month = aug,
doi = "10.1016/j.schres.2008.04.023",
language = "English (US)",
volume = "103",
pages = "104--109",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",
}